Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An International, Double-Blind, Randomized, Multi-Center, Parallel Group, Historical-Control Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (greater than or equal to 16 to 75 Years Old) With Partial Onset Seizures With or Without Secondary Generalization.

Next Previous
Trial Profile

An International, Double-Blind, Randomized, Multi-Center, Parallel Group, Historical-Control Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (greater than or equal to 16 to 75 Years Old) With Partial Onset Seizures With or Without Secondary Generalization.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brivaracetam (Primary)
  • Indications Partial epilepsies; Seizures
  • Focus Registrational; Therapeutic Use
  • Sponsors UCB

Most Recent Events

  • 15 Mar 2012 This trial has been completed in Belgium as reported by European Clinical Trials Database.
  • 15 Mar 2012 Planned number of patients changed from 178 to 223 as reported by European Clinical Trials Database.
  • 04 Jun 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top